Global Market Study on Immuno-Oncology: Immune Checkpoint Inhibitors Segment Projected to be the Most Lucrative Segment by Therapy Type


Immunooncology  Market
  • Published On : Sep-2019 |
  • Pages : 168 Pages |
  • Format : PPT PDF Excel Word

Growing Availability of Innovative and Effective Cancer Treatments to Spur Market Growth

Cancer is considered to be the second-most leading cause of death globally after cardiovascular disease. The percentage of deaths due to cancer has increased from 12% in 1990 to 15% in 2018 around the world. As per the report of World Health Organization (WHO) published in 2018, 8.3 millions of deaths are caused by cancer each year, approximately 70% of new cancer cases are expected to be reported over next 20 years.

More than 60 percent of the world’s new cancer cases occur in Africa, Asia, and Central and South America & 70 percent of the world’s cancer deaths also occur in these regions. Each type of cancer requires unique immuno-oncology treatments. Hence, increasing prevalence of cancer, and the need for personalized medicine are expected to increase the demand for immuno-oncology treatments. The rising number of cases of deaths related to cancer, and rising demand for effective and innovative immuno-oncology treatments by patients and healthcare professionals are likely to boost the growth of global immuno-oncology market.

immuno oncology market 01

Technological Advancements to Increase the Demand for Immuno-Oncology Therapy

Immuno-oncology therapy has been hailed as one of the most promising advancements for the treatment of cancer. Immuno-oncology therapy has given many research and medical communities a reason to be optimistic. Recent advancements in drug discovery and development underscore immuno-oncology therapy’s exciting potential for the future of cancer treatment.

The growing number of immuno-oncology treatments, which are in different phases of clinical trials, and the increasing approval of immuno-oncology therapies by FDA are leading to the acceptance of new and advanced technologies in the field of immuno-oncology therapy. There is very high adoption of immuno-oncology therapies in Western countries, considering they have a largely well-tolerated adverse event profile compared with conventional chemotherapy. The increasing demand for innovative immuno-oncology therapies has thus led to the growth of the immuno-oncology market at a global level.

Companion Diagnostics and Predictive Biomarkers to Shape the Future

Biomarkers and pharmacogenomics have a wide application in identification of how well patient responses to immuno-oncology therapy-based treatments, so that the overall benefits of such treatments could be maximized. Considering that, various immune resistance mechanisms have been observed in certain patients. It is desirable to identify approaches so that candidates can derive maximum therapeutic benefits.

For instance, the expression of PD-L1 on tumor cells has been identified as a prognostic biomarker in patients with advanced lung cancer treated with pembrolizumab, a PD-1 checkpoint inhibitor. Various companies have therefore been involved in co-developing companion diagnostics and seeking regulatory approval for use along with these immuno-oncology therapies, thus leading the overall growth of the immuno-oncology market.

Manufacturing Challenges Impacting Product Availability Limiting Market Growth

Manufacturers of immuno-oncology therapy-based treatments face a lot of complexity in the production and manufacturing processes. Thus, limited number of organizations are able to offer manufacturing solutions, which drug developers seek, in order to free up in-house capacity for clinical development material. Additionally, small biotech companies involved in this market rarely possess the infrastructure and capacity for commercial production.

Several contract manufacturing organizations (CMOs) are also investing in adding capabilities to manufacture complex immunotherapies, thus being able to offer solutions towards the latter part of the value chain. These factors are hampering the growth of the immuno-oncology market. Also, the high cost of the immuno-oncology therapy-based treatment is expected to limit the growth of the market in the near future.

Analysts’ Viewpoint

A comprehensive view of the immuno-oncology market has led our analysts to conclude that, the market is growing at an impressive rate, with North America and Europe holding a large chunk of the global demand for immuno-oncology therapy. Increasing acceptance of immuno-oncology therapy-based treatments, especially in developed countries like the U.S, Mexico, and Germany is spurring the growth of the global immuno-oncology market. Furthermore, the higher adoption of immuno-oncology therapies in Western countries, considering they have a largely well-tolerated adverse event profile compared with conventional chemotherapy is more likely to support the growth of the immuno-oncology market over the forecast period. The immuno-oncology market is expected to have a robust growth in the forecast period in countries of the Asia Pacific region. This is attributed to the rising prevalence of cancers and increasing demand for immuno-oncology therapies over chemotherapy in the region.

Also, increasing demand for biomarkers-based immuno-oncology therapy is anticipated to create more opportunities for immuno-oncology market players. In addition, the growing awareness for early detection and treatment of cancers is fueling the growth of the immuno-oncology market. However, factors such as high drug pricing, development costs and limited technical expertise are projected to deter the growth of the immuno-oncology market over the forecast period.

Persistence Market Research (PMR) recently published a market study on the global market for immune-oncology. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the immuno-oncology market structure. The market study presents exclusive information about how the immuno-oncology market will grow during the forecast period of 2019-2029.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the immuno-oncology market during the forecast period.

The study is relevant for stakeholders in the immuno-oncology market, including immuno-oncology therapy manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the immuno-oncology market, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in PMR’s study.

The study also includes statistics as well as facts related to macro as well as microeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the immuno-oncology market. Furthermore, small businesses and new entrants in the immuno-oncology market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.

Key Segments of the Immuno-Oncology Market

PMR’s study on the immuno-oncology market offers information divided into four important segments-therapy type, therapeutic area, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Therapy Type

Therapeutic Area

End User

  Region

  • Immune Checkpoint Inhibitors
    • PD-1
    • PD-L1
    • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others (Immune Cell Therapy, etc.)
  • Melanoma
  • Lung Cancer
  • Blood Cancers
  • Renal Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer
  • Other Cancers
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Questions Answered in PMR’s Immuno-Oncology Market Report

  • Which regions will continue to remain the most profitable regional markets for immuno-oncology market players?
  • Which factors will induce a change in the demand for immuno-oncology therapy during the assessment period?
  • How will changing trends impact the immuno-oncology market?
  • How can market players capture the low-hanging opportunities in the immuno-oncology market in developed regions?
  • Which companies are leading the immuno-oncology market?
  • What are the winning strategies of stakeholders in the immuno-oncology market to upscale their position in this landscape?

Immuno-Oncology Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the immuno-oncology market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of the conclusions.

Secondary resources referred to analysts during the production of the immuno-oncology market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in the immuno-oncology market, and makes PMR’s projection on the growth prospects of the immuno-oncology market more accurate and reliable.

Company Profiles

  • Amgen, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG 
  • Pfizer Inc.
  • Sanofi.

 

Back To Top